title: Effect of latanoprost or 8-iso prostaglandin E2 alone and in combination on intraocular pressure in glaucomatous monkey eyes.
abstract: OBJECTIVE
  To evaluate the possible additivity of the effects of latanoprost and 8-iso prostaglandin E2 (8-iso PGE2) on intraocular pressure (IOP) in monkey eyes with laser-induced glaucoma.
  
  
  METHODS
  The IOP was measured hourly for 6 hours beginning at 9:30 AM on day 1 (baseline day), days 6 and 7 (single-agent therapy), and days 13 and 14 (combination therapy with both agents). Following 1 day of baseline measurement, 4 monkeys with unilateral glaucoma received monotherapy) twice daily with either 1 drop of 0.005% latanoprost, or 0.1% 8-iso PGE2, 25 microL, at 9:30 AM and 3:30 PM from days 2 through 7. From days 8 through 14, both agents were applied twice daily 5 minutes apart.
  
  
  RESULTS
  The maximum reduction of IOP (mean +/- SEM) was 8.8 +/- 1.9 mmHg (26%) (P<.05) with latanoprost alone and 6.5 +/- 1.0 mmHg (21%) (P<.0l) with 8-iso PGE2 alone, 2 hours after the morning dosing on day 7. A further reduction of IOP of 4.0 +/- 0.6 mm Hg was produced when 8-iso PGE2 was added to latanoprost and of 3.0 +/- 0.7 mm Hg was produced when latanoprost was added to 8-iso PGE2 on day 13 before the morning dosing. Combination therapy with both agents caused maximum IOP reductions from baseline of 11.3 +/- 3.0 mm Hg (33%) (P<.05) (latanoprost with 8-iso PGE2 added) and of 9.8 +/- 1.3 mm Hg (31%) (P<.01) (8-iso PGE2 with latanoprost added) on day 14.
  
  
  CONCLUSIONS
  Latanoprost and 8-iso PGE2 have an additive effect on IOP in glaucomatous monkey eyes.
  
  
  CONCLUSIONS
  At least 50% of patients are treated with more than 1 ocular hypotensive medication. Thus, the determination of the additive effects on IOP of glaucoma medications will help to define optimum treatment regimens.
authors.affiliation: Department of Ophthalmology, Mount Sinai School of Medicine of New York University, New York, USA.
authors.forename: R F
authors.initials: RF
authors.lastname: Wang
authors.forename: S M
authors.initials: SM
authors.lastname: Podos
authors.forename: J B
authors.initials: JB
authors.lastname: Serle
authors.forename: T W
authors.initials: TW
authors.lastname: Mittag
authors.forename: F
authors.initials: F
authors.lastname: Ventosa
authors.forename: B
authors.initials: B
authors.lastname: Becker
mesh_terms: D000818:Animals; D015232:Dinoprostone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D007429:Intraocular Pressure / Q000187:drug effects*; D007536:Isomerism; D028421:Isoprostanes; D000077338:Latanoprost; D008252:Macaca fascicularis; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D028421:Isoprostanes; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D015232:Dinoprostone; C011987:8-isoprostaglandin E2